Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TTI 1612

Drug Profile

TTI 1612

Alternative Names: Soluble HB-EGF like growth factor - Trillium Therapeutics Inc; Soluble heparin-binding epidermal growth factor-like growth factor - Trillium Therapeutics Inc; TTI-1612

Latest Information Update: 29 Nov 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Trillium Therapeutics
  • Class Anti-inflammatories; Cytoprotectives; Growth factors; Recombinant proteins; Urologics
  • Mechanism of Action Epidermal growth factor receptor agonists; Epithelial cell stimulants; Intracellular signalling peptide and protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Necrotising enterocolitis
  • New Molecular Entity No
  • Available For Licensing Yes - Interstitial cystitis

Highest Development Phases

  • No development reported Interstitial cystitis
  • Discontinued Necrotising enterocolitis

Most Recent Events

  • 17 Nov 2021 Trillium Therapeutics Inc has been acquired by Pfizer
  • 02 Jun 2014 Stem Therapeutics changes its name to Trillium Therapeutics
  • 16 May 2013 TTI 1612 is still available for partnering as of 16 May 2013. www.stemcellthera.com
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top